Показать сообщение отдельно
  #4  
Старый 09.07.2011, 18:08
Аватар для easl
easl easl вне форума
Врач-инфекционист
      
 
Регистрация: 05.02.2008
Адрес: Баку
Сообщений: 17,656
Поблагодарили 4,948 раз(а) за 4,710 сообщений
easl этот участник имеет превосходную репутацию на форумеeasl этот участник имеет превосходную репутацию на форумеeasl этот участник имеет превосходную репутацию на форумеeasl этот участник имеет превосходную репутацию на форумеeasl этот участник имеет превосходную репутацию на форумеeasl этот участник имеет превосходную репутацию на форумеeasl этот участник имеет превосходную репутацию на форумеeasl этот участник имеет превосходную репутацию на форумеeasl этот участник имеет превосходную репутацию на форумеeasl этот участник имеет превосходную репутацию на форумеeasl этот участник имеет превосходную репутацию на форуме
Telaprevir Alone or with Peginterferon and Ribavirin Reduces HCV RNA in Patients with Chronic Genotype 2 but Not 3 Infections
Graham R. Foster1, , , Christophe Hézode2, Jean-Pierre Bronowicki3, Giampiero Carosi4, Ola Weiland5, Lieselotte Verlinden6, Rolf van Heeswijk6, Ben van Baelen6, Gaston Picchio7 and Maria Beumont6

1 Queen Marys University of London, Blizard Institute of Cellular and Molecular Science, London, UK

2 Hôpital Henri-Mondor, AP-HP, Université Paris XII, Créteil, France

3 INSERM954, Centre Hospitalier Universitaire de Nancy, Université Henri Poincaré Nancy 1, Vandoeuvre-lès-Nancy, France

4 Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy

5 Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden

6 Tibotec BVBA, Beerse, Belgium

7 Tibotec Inc., Titusville, NJ, USA

Received 8 December 2010; revised 12 April 2011; accepted 16 May 2011. Available online 31 May 2011.

Abstract
Background & Aims
We evaluated antiviral activity of 2 weeks therapy with telaprevir alone (T), peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in treatment-naïve patients with chronic hepatitis C virus (HCV) genotype (G) 2 or 3 infections.

Methods
We performed a randomized, multicenter, partially-blinded study of patients (23 with HCV G2, 26 with G3) who received telaprevir (750 mg every 8 hours) , placebo plus PR (Peg-IFN, 180 μg, once weekly and RBV, 400 mg, twice daily), or TPR for 15 days, followed by PR for 22 or 24 weeks. We quantified levels of HCV RNA in plasma.

Results
Levels of HCV RNA decreased in all patients with HCV G2, including those that received telaprevir monotherapy. The decrease was faster among patients that received telaprevir. By Day 15, 0 (telaprevir), 40% (TPR), and 22% (PR) of patients with HCV G2 had undetectable levels of HCV RNA; rates of sustained virologic response (SVR) were 56%, 100%, and 89%, respectively. Overall, 6/9 HCV G2 patients that received only telaprevir had viral breakthrough within 15 days. HCV RNA levels decreased slightly among patients with HCV G3 who received telaprevir, and decreased rapidly among patients given PR or TPR (telaprevir had no synergistic effects). SVR rates were 50%, 67%, and 44% among patients given telaprevir, TPR, or PR respectively; 7 patients with HCV G3 relapsed after therapy (2 given telaprevir, 3 given TPR, and 2 given PR) and 3 patients with HCV G3 had viral breakthrough during telaprevir monotherapy. The incidence of adverse events was similar among groups.

Conclusions
Telaprevir monotherapy reduces levels of HCV RNA in patients with chronic HCV G2 infections, but has limited activity in patients with HCV G3.



Corresponding author: Graham R Foster, Queen Marys University of London, Blizard Institute of Cellular and Molecular Science, Barts and The London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, Phone: (+44) 207 882 7242, Fax: (+44) 207 882 2187
[Ссылки доступны только зарегистрированным пользователям ]
__________________
С уважением, Юсиф Алхазов.
Ответить с цитированием